Font Size:
a
A
A
Keyword [TKI-resistance]
Result: 1 - 20 | Page: 1 of 3
1.
Study Of Synergism Between Cisplatin And Gefitinib In Gefitinib Resistant Non-small Cell Lung Cancer
2.
EPAS1 And MiR-200a Confers TKI-resistance By Mediating EGFR In Non-small Lung Cancer Cells
3.
RNA Activation Reverses TKI Resistance In EGFR-mutant NSCLC Patients By Upregulating PTEN Expression
4.
Mechanism Of Hedgehog Signaling Pathway In EGFR-TKI Sensitive And Resistance NSCLC Cells
5.
Investigation On The EGFR-TKI Resistance Mechanisms Of NSCLC With EGFR Mutations In Vitro
6.
A Comparison Of Two Methods For Detecting EGFR T790M Status From Advanced NSCLC Patients With Acquired EGFR-TKI Resistance And Clinical Analysis
7.
Chemotherapy On T790M Mutation Status In Patients With Advanced NSCLC After EGFR-TKI Resistance
8.
The Effects And Molecular Mechanisms Of Autophage Regulated By PSMC2 Through UPS In Acquired EGFR-TKI Resistance Of Non Small-cell Lung Cancer (NSCLC)
9.
Reverse EGFR-TKI Resistance In NSCLC By Shikonin And Construct Shikonin Nanoparticles
10.
MiR-1 And Restoring The Sensibility Of EGFR-TKI Resistance In NSCLC
11.
Expression Of MiR-125 In Serum Before And After EGFR-TKIs Acquired Resistance In NSCLc And Its Clinical Significance
12.
The Mechanism Of N-Acetyl-L-Cysteine In Reversing EGFR-TKI Resistance Induced By Cigarette Smoke Extract In NSCLC Cell Lines
13.
Expression And Clinical Significance Of P53 And COX-2 Protein In Patients With EGFR Mutant Advanced Lung Adenocarcinoma
14.
The Correlation Between T790M Gene Mutation Of Non-small Cell Lung Cancer And Efficacy Of EGFR-TKI
15.
The Mechanism Study Of Efatutazone Reverse Acquired EGFR-TKI-Resistance In NSCLC
16.
Clinical And Molecular Characteristics Of MET/T790M Coexistence And Resistence Mechanism Of MET-TKI In Advanced Non-small Cell Lung Cancer
17.
The Investigation On Molecular Mechanism Of Acquired Resistance In EGFR-TKI Resistance Cell Line HCC827-TR
18.
The Prognosis Of Segmentectomy And Adjuvant EGFR TKI Treatment For Early-stage Non-small-cell Lung Cancer And The Mechanisms Of 3
rd
-generation TKI Resistance
19.
Co-administration Of 20(S)-protopanaxatriol (g-PPT) And EGFR-TKI Overcomes EGFR-TKI Resistance By Decreasing SCD1 Induced Lipid Accumulation In Non-small Cell Lung Cancer
20.
Rab25 And TAM M2 Polarization Promote Erlotinib Resistance In NSCLC
<<First
<Prev
Next>
Last>>
Jump to